Share-based Payment Arrangement, Expense of 89bio, Inc. from 31 Dec 2018 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
89bio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Jun 2025.
  • 89bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $7,315,000, a 42% increase year-over-year.
  • 89bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $24,998,000, a 35% increase year-over-year.
  • 89bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20,634,000, a 28% increase from 2023.
  • 89bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $16,106,000, a 56% increase from 2022.
  • 89bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,356,000, a 19% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

89bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $24,998,000 $7,315,000 +$2,146,000 +42% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $22,852,000 $7,216,000 +$2,218,000 +44% 01 Jan 2025 31 Mar 2025 10-Q 02 May 2025 2025 Q1
Q4 2024 $20,634,000 $5,205,000 +$1,168,000 +29% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $19,466,000 $5,262,000 +$881,000 +20% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $18,585,000 $5,169,000 +$1,032,000 +25% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $17,553,000 $4,998,000 +$1,447,000 +41% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2025 2025 Q1
Q4 2023 $16,106,000 $4,037,000 +$1,279,000 +46% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $14,827,000 $4,381,000 +$1,881,000 +75% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $12,946,000 $4,137,000 +$1,551,000 +60% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $11,395,000 $3,551,000 +$1,039,000 +41% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $10,356,000 $2,758,000 +$604,000 +28% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $9,752,000 $2,500,000 +$186,000 +8% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $9,566,000 $2,586,000 +$169,000 +7% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $9,397,000 $2,512,000 +$719,000 +40% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $8,678,000 $2,154,000 +$904,000 +72% 01 Oct 2021 31 Dec 2021 10-K 01 Mar 2024 2023 FY
Q3 2021 $7,774,000 $2,314,000 +$1,160,000 +101% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $6,614,000 $2,417,000 +$1,507,000 +166% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $5,107,000 $1,793,000 +$1,300,000 +264% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $3,807,000 $1,250,000 +$1,084,000 +653% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $2,723,000 $1,154,000 +$1,042,000 +930% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,681,000 $910,000 +$834,000 +1097% 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $847,000 $493,000 +$458,000 +1309% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q4 2019 $389,000 $166,000 01 Oct 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 $112,000 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $76,000 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $35,000 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1

89bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $20,634,000 +$4,528,000 +28% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $16,106,000 +$5,750,000 +56% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $10,356,000 +$1,678,000 +19% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $8,678,000 +$4,871,000 +128% 01 Jan 2021 31 Dec 2021 10-K 01 Mar 2024 2023 FY
2020 $3,807,000 +$3,418,000 +879% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $389,000 +$281,000 +260% 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2018 $108,000 18 Jan 2018 31 Dec 2018 10-K 18 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.